NL-OMON33645尚未招募2 期
Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia A - IMP 12781/LIPLONG
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- Bayer
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Males aged 18 to 70 years
- •- Subjects with severe hemophilia A (< 1% FVIII:C)
- •- Subjects with equal or greater than 150 EDs with any FVIII in total
- •- Subjects who have been on-demand treatment (no more than 40% of patients and at least 20% are high-frequency bleeders [>=20 bleeds/year]) with an average of minimum 1 relevant bleed per month or have been on secondary prophylaxis treatment with not more than a 3x/week schedule with the history of minimum 12 relevant bleeds per year prior to be on secondary prophylaxis treatment
- •- Subjects with bleeding events and/or treatments during the last 6 months prior to study entry which are documented in the subjects medical records.
- •- Subjects with no measurable inhibitor activity using the Nijmegen-modified Bethesda assay (>0.6BU/mL is considered positive) in two consecutive samples and absence of clinical signs or symptoms of decreased response to FVIII administration.
- •- Subjects with no history of FVIII inhibitor antibody formation. (>=0.6BU/mL using the Nijmegen-modified Bethesda assay)
- •- Subjects who complete an EPD (electronic patient diary) device training and demonstrate the ability to correctly use it
排除标准
- •- Subjects who are receiving primary prophylaxis (start of prophylaxis before or directly after the first joint bleed without relevant interruptions)
- •- Subjects on prophylaxis with documented requirements of > 75 IU/kg/week
- •- Subjects with any other bleeding disease beside hemophilia A (i.e., von Willebrand disease)
- •- Subjects with thrombocytopenia (platelets < 100,000/mm3)
- •- Subjects with abnormal renal function (serum creatinine > 2.0 mg/dL)
- •- Subjects with elevated hepatic transaminases (AST or ALT > 5xULN)
- •- Subjects on treatment with immunomodulatory agents within the last 3 months prior to study entry or during the study (the following drugs are allowed: interferon-alpha-treatment for HCV, HAART therapy for HIV and/or a total of two courses of pulse treatment with steroids for a maximum of 7 days at 1mg/kg or less)
- •- Subjects with an absolute CD4 lymphocyte cell count < 250 cells/mm3
- •- Subjects with positive Lupus Anticoagulant antibodies or history thereof
- •- Subjects with known hypersensitivity to the active substance, mouse or hamster protein, liposomes or PEG
- •- Subjects with severe dyslipidemia of all causes LDL-C >= 190 mg/dl)
- •- Subjects who are receiving or had received other experimental drugs within 3 months prior to study entry
- •- Subjects who require any pre-medication for FVIII injections (e.g. anti-histamines)
- •- Subjects with uncontrollable hypertension (diastolic blood pressure > 100 mmHg)
- •- Subjects with known unstable coronary artery angina and/or with known history of myocardial infarction.
- •- Subjects who are unwilling to comply with study visits or the treatment regimens
- •- Subjects who have planned major surgery (including orthopedic) or radioisotopic synovectomy during the study
- •- Subjects who are not suitable for participation in this study for any reason, according to the Investigator
研究者
相似试验
进行中（未招募）
不适用
Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia A. - NDSevere hemophilia AMedDRA version: 9.1Level: LLTClassification code 10056493Term: Haemophilia A without inhibitorsEUCTR2007-003718-32-ITBAYER250
进行中（未招募）
1 期
Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia AHemophilia AEUCTR2007-003718-32-NOBayer HealthCare AG250
进行中（未招募）
不适用
Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia AHemophilia AEUCTR2007-003718-32-DKBayer HealthCare AG100
进行中（未招募）
1 期
Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia AMedDRA version: 9.1Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)MedDRA version: 9.1Level: LLTClassification code 10018937Term: Haemophilia AHemophilia AEUCTR2007-003718-32-FRBayer HealthCare AG143
进行中（未招募）
不适用
Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia AHemophilia AEUCTR2007-003718-32-DEBayer HealthCare AG100